Novartis (SWX:NOVN) is back in focus after the European Medicines Agency’s CHMP issued a positive opinion for Cosentyx in polymyalgia rheumatica, highlighting both the product portfolio and the wider immunology pipeline.

Recent trading has been choppy. The share price is down about 9.5% over the past month but still shows a 6.1% gain year to date, while the 1-year total shareholder return of 21.3% points to momentum that has been building over a longer stretch.

Scan how Novartis fits into the wider opportunity set by comparing it with a hand picked 179 high quality undervalued stocks that also pair solid balance sheets with cash flows the market may be discounting.

After a sharp pullback to CHF 115.10, while analyst targets and intrinsic value estimates sit higher, the real question is where fair value for Novartis actually lands within that range.

Most Popular Narrative: 9% Undervalued

On the current narrative, Novartis screens as modestly undervalued, with a fair value estimate of CHF126.13 set against the last close at CHF115.10. That gap is not huge, but it reflects a view that the pipeline and cash generation still justify a little more optimism than the recent share pullback implies.

Novartis’ robust pipeline and rapid regulatory progress in advanced therapies (including biologics, gene, and cell therapies) positions the company to benefit from emerging healthcare technologies. This may potentially support future earnings and margin growth as new high-value products launch. Expansion in emerging markets, particularly China (with Leqvio’s strong out-of-pocket uptake and continued ex-U.S. growth in priority brands), increases Novartis’ overall addressable market, which may help mitigate saturation in developed geographies and support future sales and cash flow.

See why 107 investors see Novartis as 9% undervalued.

Result: Fair Value of CHF126.13 (UNDERVALUED)

Still, the narrative can crack if patent expiries on key drugs bite harder than expected, or if pricing reforms in major markets compress profitability faster than analysts model.

Find out about the key risks to this Novartis narrative.

Next Steps

Mixed signals on Novartis so far, with risks and rewards both on the table, mean this is a moment to move quickly and test the data for yourself. To see that balance clearly, review the 3 key rewards and 1 important warning sign.

Looking for more Novartis sized investment ideas?

If Novartis has your attention, do not stop here. Broaden your watchlist and stress test your thinking with a few targeted stock shortlists.